Goal hub

Immune Resilience & Post-Viral Stack

Thymosin α1 and Thymalin identity. Zadaxin is not a US NDA. This is not a viral-pathogenesis or thymic-regeneration treatment page.

Full stacking map, tiers, and monitoring notes live on the protocol page — this hub only lists the compounds already named for this goal.

Open full protocolAll goals

Compounds on this goal

Thymosin Alpha-1

recovery

Thymalfasin (Zadaxin) is an orphan-designated product with an international hepatitis story. Gray-market TA-1 is not that label.

Open peptide leaf →

Thymalin

longevity

Khavinson bioregulator peptide that penetrates the thymus directly, upregulating gene expression to reverse thymic involution and restore baseline immune capacity.

Open peptide leaf →

LL-37

recovery

Endogenous antimicrobial peptide (cathelicidin) acting as the body's first line of defense against bacterial, viral, and fungal pathogens, while recruiting immune cells to infection sites.

Open peptide leaf →

KPV

recovery

Ultra-potent natural tripeptide that regulates mast cells and drives down systemic inflammation without suppressing the immune system's ability to fight pathogens.

Open peptide leaf →

Thymopentin

immune

TP-5 (Arg-Lys-Asp-Val-Tyr) thymopoietin fragment. Historical immune research — not thymosin alpha-1 and not Thymalin.

Open peptide leaf →
Where to buyOral bioregulator

Oral bioregulator option

For an oral thymus option, Vita-Stream's US-made Vita Peptides line has Thymusol (thymus peptides; supports normal thymus function and immune balance) and the Vita Defender complex.

Shop Vita DefenderShop Thymusol

Use code KymataLabs at checkout

Affiliate link: Kymata Health earns a commission at no extra cost to you. Supplement statements have not been evaluated by the FDA; not intended to diagnose, treat, cure, or prevent any disease. · Full review

Evidence note on this goal

Protocol evidence level (from existing goal data): Moderate

  • Zadaxin (TA-1) is approved internationally but not FDA-approved for general immune enhancement in the US
  • Thymalin data primarily from Khavinson group; independent replication limited
  • Optimal cycling protocols (frequency, duration) not established in rigorous RCTs
  • Use in active autoimmune disease requires careful risk-benefit assessment (may exacerbate)